Melissa Glasner: The Safe and Effective Implementation of FXI/XIa Inhibitors Into Clinical Practice
Melissa Glasner, Medical Content Manager at The France Foundation, shared on LinkedIn about a recent article she and her colleagues co-authored, published in RPTH, adding:
”I am very pleased to announce the publication of the first of three manuscripts by the ISTH FXI/XIa Steering Committee.
As FXI/XIa inhibitors move closer to clinical practice, this review highlights the critical role of laboratory testing, assay standardization, and multidisciplinary collaboration in supporting their safe and effective implementation.
Thank you to my co-authors, especially Dave Gailani and Jeffrey Weitz, for their assistance, guidance, and mentorship throughout the development of this manuscript.
A special shout-out, as always, to Miriam Giles for keeping us organized during the submission and peer review process – couldn’t have done it without you!”
Title: Measuring up: the need for new assays for factor (F)XI/FXIa inhibitor therapies
Authors: Melissa F. Glasner, David Gailani, Rasha Al-Lamee, María Cecilia Bahit, Jonathan Coutinho, Clay Johnston, Wolfgang C. Winkelmayer, Jeffrey Weitz
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 4, 2026, 18:49Børge Nordestgaard: Lp(a) Remains a Risk Factor Across the Lifespan
-
Sep 4, 2026, 18:22Tareq Abadl: The Clinical Meaning of C3 and C4
-
Sep 4, 2026, 18:16How Mutant p53 Hijacks VWF Expression in Tumor Cells – JTH
-
Sep 4, 2026, 18:08Simon Kraler: Can the Adrenomedullin System Predict Cardiogenic Shock Before It Happens?
-
Sep 4, 2026, 17:56Maxime Dely: Why Every Blood Donation Matters
-
Sep 4, 2026, 17:28Shinya Goto: When Cardiovascular Risk Gets Lower, RCTs Get Harder
-
Sep 4, 2026, 16:55New Orleans Is Calling ASH26 Is Near
-
Sep 4, 2026, 16:48ESC Congress 2026 – My Top 20 Lipidology Highlights Shaping the Future of Cardiovascular Prevention – Pablo Corral
-
Sep 4, 2026, 16:38Felice Gragnano։ Turning Cardiovascular Risk Into Action